EGFR tyrosine kinase inhibitors as first-line therapy in advanced EGFR mutation-positive non-small cell lung cancer: strategies to improve clinical outcome.

Tiefenbacher, Andreas; Pirker, Robert

Tiefenbacher, Andreas; Pirker, Robert.

Afiliação

Tiefenbacher A; Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Pirker R; Department of Medicine I, Medical University of Vienna, Vienna, Austria.

J Thorac Dis ; 9(11): 4208-4211, 2017 Nov.

Article em En | MEDLINE | ID: mdl-29268473

Texto completo

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720983
https://dx.doi.org/10.21037/jtd.2017.10.02

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720983
https://dx.doi.org/10.21037/jtd.2017.10.02

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article